Artificial intelligence has the potential to change the way physicians have monitored for conditions such as atrial fibrillation in the past 5 decades, said Brandon Fornwalt, MD, PhD, director of the Cardiac Imaging Technology Laboratory at Geisinger.
Artificial intelligence has the potential to change the way physicians have monitored for conditions such as atrial fibrillation in the past 5 decades, said Brandon Fornwalt, MD, PhD, director of the Cardiac Imaging Technology Laboratory at Geisinger.
Transcript
Can you discuss the initial intrigue in artificial intelligence for both electrocardiogram (ECG) trace studies? What must physicians and patients understand about its efficacy?
Electrocardiograms are a very widely used test in medicine. Most patients by the end of their lives have undergone an electrocardiogram at some point. We've spent a lot of time over the last many decades understanding how to do automated computer analysis of electrocardiogram data. Recently, artificial intelligence algorithms have improved, and data sets have gotten larger, and now we can use different approaches called deep learning to further analyze these signals that we collect from patients. So, the intrigue is, can we start to use deep learning to tell us insights about patients that are going to help us treat them better.
As far as efficacy is concerned, we have spent a lot of time building models where we know we can predict in a bunch of data fairly accurately what the likelihood of these events will be in the future; but what physicians and patients need to understand is that it's going to take a lot of prospective clinical trials to really demonstrate that when we know that prediction—we can actually impact an outcome that a patient cares about, for example, reduce the risk of stroke or reduce the risk of mortality.
Based on study results showing that AI predicted one-year risk of atrial fibrillation (AF) directly from ECG traces, can you discuss the preventive significance of the deep neural network as an accurate predictor of AF?
We had a couple of interesting findings in the studies. We’re trying to find ways in which these algorithms can add value above and beyond what a physician already does. Physicians do a ton of really good stuff with electrocardiogram data, and what we found is that we have prediction power to predict these future clinical events like atrial fibrillation and mortality in the broad population of patients that undergoes electrocardiogram. Then, building on that concept of doing something above and beyond what a physician does, we looked at cases where the physician called these ECGs normal. So, that means they said, look, there's nothing wrong here—move on next case, normal electrocardiogram. Now, the models still had prediction power inside of those ECGs, and that means that the model is latching on to things that right now as physicians, we either recognize them and think they're clinically insignificant, or we don't recognize them at all. That's what we think is really cool about AI in medicine is, it’s going to come in and potentially teach us things that can change the way we've been doing something for the last 5 decades.
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More